风湿性心脏病二尖瓣置换:生物瓣与机械瓣的长期结局比较
基于台湾全民健康保险研究数据库2000至2013年3638例风湿性心脏病二尖瓣置换患者,经倾向评分1:1匹配后各788例比较。生物瓣组全因死亡风险(HR 1.19,95%CI 1.01-1.41,P=.040)和二尖瓣再手术风险(sHR 4.56,95%CI 1.71-12.17,P<.01)均高于机械瓣组,机械瓣的生存获益在65岁以下患者中更明显。
要点
- 风湿性心脏病二尖瓣置换中,生物瓣长期全因死亡风险高于机械瓣。
- 生物瓣二尖瓣再手术风险显著高于机械瓣(sHR 4.56)。
- 机械瓣的生存获益在65岁以下患者中更明显。
核心结论
- 风湿性心脏病二尖瓣置换患者中,机械瓣与更优的长期结局相关,尤其见于65岁以下患者。
研究设计与样本
- 回顾性队列研究,数据来自台湾全民健康保险研究数据库2000至2013年。
- 共纳入3638例风湿性心脏病二尖瓣置换患者,生物瓣1075例(29.5%)、机械瓣2563例(70.5%)。
- 采用1:1倾向评分匹配,匹配后每组各788例。
主要发现
- 院内死亡风险两组无显著差异(P=.920)。
- 生物瓣组全因死亡风险更高:10年生存率估计50.6% vs 45.5%,HR 1.19(95%CI 1.01-1.41),P=.040。
- 生物瓣组二尖瓣再手术风险更高:10年估计8.9% vs 0.93%,sHR 4.56(95%CI 1.71-12.17),P<.01。
- 机械瓣的死亡获益在年轻患者中更明显,并持续至约65岁。
临床怎么用
- 风湿性心脏病二尖瓣置换选择瓣膜类型时,对65岁以下患者可优先考虑机械瓣以改善长期生存并降低再手术风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rheumatic heart disease (RHD) remains a critical problem in developed countries. Few studies have compared the long-term outcomes of bioprosthetic valves and mechanical valves in patients with RHD who have received mitral valve (MV) replacement. METHODS: Patients with RHD who received MV replacement with bioprosthetic or mechanical valves were identified between 2000 and 2013 from Taiwan's National Health Insurance Research Database. The primary late outcomes of interest were all-cause mortality and redo MV surgery. Propensity score matching at a 1:1 ratio was performed. RESULTS: We identified 3638 patients with RHD who underwent MV replacement. Among those patients, 1075 (29.5%) and 2563 (70.5%) chose a bioprosthetic valve and mechanical valve, respectively. After matching, 788 patients were assigned to each group. No significant difference in the risk of in-hospital mortality was observed between groups (P = .920). Higher risks of all-cause mortality (10-year actuarial estimates: 50.6% vs 45.5%; hazard ratio, 1.19; 95% confidence interval, 1.01-1.41; P = .040) and MV reoperation (10-year actuarial estimates: 8.9% vs 0.93%; subdistribution hazard ratio, 4.56; 95% confidence interval, 1.71-12.17; P <.01) were observed in the bioprosthetic valve group. Furthermore, the relative mortality benefit associated with mechanical valves was more apparent in younger patients and the beneficial effect persisted until approximately 65 years of age. CONCLUSIONS: In the patients with RHD who underwent MV replacement, mechanical valves were associated with more favorable long-term outcomes in patients younger than the age of 65 years.
引用
- Chen CY, Chan YH, Wu VC, et al. Bioprosthetic versus mechanical mitral valve replacements in patients with rheumatic heart disease. J Thorac Cardiovasc Surg. 2021. PMID: 33840468. doi:10.1016/j.jtcvs.2021.03.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。